Verastem Oncology (VSTM) Tops Q3 EPS by 8c

Verastem Oncology (NASDAQ: VSTM) reported Q3 EPS of ($0.71), $0.08 better than the analyst estimate of ($0.79).

For earnings history and earnings-related data on Verastem Oncology (VSTM) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Eltek Ltd (ELTK) Reports Q2 EPS of $0.41
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance